Last reviewed · How we verify
Placebo , Oxaliplatin
Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication.
Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication. Used for Metastatic colorectal cancer (in combination with fluorouracil and leucovorin), Adjuvant treatment of stage III colon cancer.
At a glance
| Generic name | Placebo , Oxaliplatin |
|---|---|
| Sponsor | University of Sao Paulo |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Oxaliplatin is a third-generation platinum compound that binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA synthesis and triggering apoptosis in cancer cells. It is often used in combination chemotherapy regimens, particularly for colorectal cancer. The drug has a different spectrum of activity and toxicity profile compared to earlier platinum agents like cisplatin.
Approved indications
- Metastatic colorectal cancer (in combination with fluorouracil and leucovorin)
- Adjuvant treatment of stage III colon cancer
Common side effects
- Peripheral neuropathy
- Nausea and vomiting
- Diarrhea
- Fatigue
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (PHASE2)
- A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (PHASE2)
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo , Oxaliplatin CI brief — competitive landscape report
- Placebo , Oxaliplatin updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI